ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RDNT / forecast
BLLN (70) GRAL (54) CON (68) CDNA (71) ⌘ Pro Terminal →

RadNet Inc. (RDNT) 12-Month Stock Forecast & Price Target Cone

$73.10 -0.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $72.89

RadNet Inc. (RDNT) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $5.78B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RDNT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RDNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, RadNet Inc. (NASDAQ: RDNT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $73.10 (-0.53% 1D, market cap $5.78B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, RDNT ranks #189 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RDNT compare to BLLN and GRAL in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), RDNT carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 3.5%. By comparison, BLLN (BillionToOne Inc.) holds a B- grade (70/100 RQD, P/E N/A, ROIC 2.9%, cap $5.35B) and GRAL (GRAIL Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -18.0%, cap $6.41B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RDNT?
▼

Per RDNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000790526), RadNet Inc. generated $2.04B in revenue (+11.5% YoY), -$18.6M in net income, and $298.8M in free cash flow against $3.76B in total assets and $1.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $72.89 (-0.29%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 14.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D+
Cash (12)Whales (14)SEC (10)Macro (11)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE-0.5% Base Target
$90 Bull$73 Base$57 Bear
📬 FREE RDNT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RDNT)Realized 20D OHLCV Swing Band: ±6.6%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY RDNT SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (25% of score)

20D Institutional Volume Accumulation (±6.6% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 14.6% FCF Margin ($298.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution10/20 pts (-10 pt drag)

Cannibal Buyback (-0.68% YoY Shares) & executive Form 4 sales trim 10 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$71.49-3.1% Next Q
Q2 (-2Q)
52
Grade C-$69.27+1.1% Next Q
Q3 (-1Q)
54
Grade C-$70.05+4.4% Next Q
Current
57
Grade D+$73.10-0.2% Hist 90D α
Trajectory: D (49) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RDNT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, RDNT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.49) or 200D SMA ($65.14) invalidates the momentum regime and cuts Target Base ($72.77) toward Bear Floor ($56.76).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RDNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RDNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 57%NO 43%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RDNT Position Size: $10,000

Shares at $73.10: 136.8 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $56.76
$7,765
$-2,235 (-22.4%)
12M Consensus BaseTarget $72.77
$9,955
$-45 (-0.5%)
12M Bull Case BreakoutTarget $90.13
$12,330
+$2,330 (+23.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$7674%A
Goldman SachsSector Coverage LeadUNDERPERFORM$8569%B
JP MorganUS Large-Cap ResearchSELL$6558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RDNT)

  • ✓Walkthrough of RDNT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RDNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.47%▲ ASCENDING CHANNEL
2026-11-03O $73.65H $73.65L $73.10C $73.10VOL 571.7K
RES: $81.01SUP: $68.68SMA50: $72.49SMA200: $65.14
$81.80$73.40$65.01$56.61$48.21RES $81.01SUP $68.68$73.102026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RDNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RDNT Butterfly Map → + Track RDNT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RDNT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RDNT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RDNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RDNT)

Health Care Rank #189 of 1016 ⚔️ BLLN vs RDNT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RDNT vs. BLLN, GRAL, CON, CDNA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, RadNet Inc. (RDNT) ranks #189 by composite RQD confidence (57/100, grade D+) and #148 by equity capitalization ($5.78B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. CDNA currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with RDNT at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RDNT ACTIVE
RadNet Inc.
D+ 57/100 — — 3.5% -0.53% $5.78B Benchmark Subject
BLLN
BillionToOne Inc.
B- 70/100 — 68.3% 2.9% -2.57% $5.35B /blln-vs-rdnt →
GRAL
GRAIL Inc.
D+ 54/100 — — -18.0% -6.74% $6.41B /gral-vs-rdnt →
CON
Concentra Group Holdings Parent Inc.
C+ 68/100 31.6x — 19.7% -0.12% $5.15B /con-vs-rdnt →
CDNA
CareDx Inc.
B- 71/100 — — -8.2% -1.75% $4.59B /cdna-vs-rdnt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000790526

In its most recent audited fiscal period (FY2025, filed 2025-12-31), RadNet Inc. (RDNT) reported GAAP revenue of $2.04B (+11.5% vs. FY2024 revenue of $1.83B , and +26.2% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of $298.8M, and free cash flow of $298.8M (+28.2% YoY). On the balance sheet, RDNT closed FY2025 with $3.76B in total assets against $1.06B in total debt (Altman Z-Score: 2.15, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.04B -$18.6M $298.8M $298.8M $3.76B $1.06B
FY2024 (FY) 2024-12-31 $1.83B $2.8M $233.0M $233.0M $3.29B $991.6M
FY2023 (FY) 2023-12-31 $1.62B $3.0M $220.9M $220.9M — —

3. RDNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RDNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, RadNet Inc. (NASDAQ: RDNT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $73.10 (-0.53% 1D, market cap $5.78B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, RDNT ranks #189 in composite RQD confidence.

How does RDNT compare to BLLN and GRAL in the Health Care sector?

Within the Health Care sector (Medical Specialities), RDNT carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 3.5%. By comparison, BLLN (BillionToOne Inc.) holds a B- grade (70/100 RQD, P/E N/A, ROIC 2.9%, cap $5.35B) and GRAL (GRAIL Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -18.0%, cap $6.41B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RDNT?

Per RDNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000790526), RadNet Inc. generated $2.04B in revenue (+11.5% YoY), -$18.6M in net income, and $298.8M in free cash flow against $3.76B in total assets and $1.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RDNT trading relative to its 50-day, 200-day, and 52-week technical levels?

RDNT last traded at $73.10 (-0.53% on volume of 960,789 shares), positioning the stock +0.84% above its 50-day simple moving average ($72.49) and +12.22% above its 200-day simple moving average ($65.14). Across its 52-week range of $50.82 to $85.84, RDNT sits at the 63.6% percentile with a 14-day RSI of 57.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.6% ($68.28 to $77.92).

Direct Sub-Reports: RDNT RQD Cockpit RDNT 12M Forecast RDNT Earnings & Move RDNT Dividends & DRIP RDNT Insiders & 13F RDNT Whale Options RDNT Profit Sankey RDNT News & Why
ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

RDNT — RadNet Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

RadNet Inc. (RDNT) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $73.10 (-0.53% 1D, market capitalization $5.78B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 3.5%, gross margin of —, operating margin of 3.0%, and free cash flow yield of 5.16%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.15, Piotroski F-Score of 6/9, and Debt/Equity of 0.98x.

2. Business Model, Unit Margins & SEC Financial Trajectory

RadNet Inc. Is a NASDAQ-listed issuer classified in the Health Care sector and the Medical Specialities industry,..8B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), RadNet Inc. (RDNT) reported $2.04B in annual revenue (up from $1.83B in FY2024, +11.5% YoY) and -$18.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.62B revenue, $3.0M net income) through FY2025, RDNT scaled operating cash flow to $298.8M and free cash flow to $298.8M, backed by $3.76B in total assets against $1.06B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 57/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 5.16% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $50.82 – $85.84 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 98.3x EV/EBITDA against 3.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations beyond the Health Care / Medical Specialities classification. An investor should note that second-order ripple effects cannot be mapped from the provided sources. The one cross-check the data permits is the M&A reference in the Seeking Alpha headline, which points to a possible corporate-action catalyst, but the source does not detail its counterparty or implications.

  • Key Question #1: Can RDNT sustain or expand its 3.0% operating margin and 3.5% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.04B and free cash flow of $298.8M, how will capital allocation balance growth reinvestment against $1.06B in total debt?
  • Key Question #3: How sensitive is RDNT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RDNT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for RadNet Inc. (RDNT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RDNT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RDNT Bull vs. Bear Conversation Board — What's Your Call at $73.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RDNT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RDNT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $89.66 (+22.0%)
📌 Pinned Debate

Macro Regime Fit (14/20) is the strongest pillar, with beta of 1.0 and a 5.16% FCF yield providing cash-based support against the stock

Picked up a starter position in RDNT in my $100K Virtual Cash book at $73.49. Macro Regime Fit (14/20) is the strongest pillar, with beta of 1.0 and a 5.16% FCF yield providing cash-based support against the stock's price.. Trading inside a $50.82–$85.84 52-week range with 5.16% FCF yield gives solid downside support if Medical Specialities multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — RDNT's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $57.32 (-22.0%)
Spot @ $73.49

An EV/EBITDA of 98.3 combined with a net margin of -0.9% and debt of $1.06B exceeding cash of $767.2M leaves little valuation cushion

Careful chasing RDNT at $73.49. An EV/EBITDA of 98.3 combined with a net margin of -0.9% and debt of $1.06B exceeding cash of $767.2M leaves little valuation cushion.. Gross margin is 0.0%, but operating margin is 3.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $57.32 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%